HK1225443A1 - 在心力衰竭中用於抑制素治療分層的標記物 - Google Patents

在心力衰竭中用於抑制素治療分層的標記物

Info

Publication number
HK1225443A1
HK1225443A1 HK16113784A HK16113784A HK1225443A1 HK 1225443 A1 HK1225443 A1 HK 1225443A1 HK 16113784 A HK16113784 A HK 16113784A HK 16113784 A HK16113784 A HK 16113784A HK 1225443 A1 HK1225443 A1 HK 1225443A1
Authority
HK
Hong Kong
Prior art keywords
marker
heart failure
statin treatment
treatment stratification
stratification
Prior art date
Application number
HK16113784A
Other languages
English (en)
Inventor
Dirk Block
Hanspeter Brunner
Thomas Dieterle
Ursula-Henrike Wienhues-Thelen
Christian Zaugg
André Ziegler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1225443A1 publication Critical patent/HK1225443A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16113784A 2013-08-26 2016-12-02 在心力衰竭中用於抑制素治療分層的標記物 HK1225443A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13181687.8A EP2843414B1 (en) 2013-08-26 2013-08-26 Marker for statin treatment stratification in heart failure

Publications (1)

Publication Number Publication Date
HK1225443A1 true HK1225443A1 (zh) 2017-09-08

Family

ID=49029008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16113784A HK1225443A1 (zh) 2013-08-26 2016-12-02 在心力衰竭中用於抑制素治療分層的標記物

Country Status (7)

Country Link
US (3) US10234464B2 (zh)
EP (2) EP3441768A3 (zh)
JP (3) JP6625535B2 (zh)
CN (2) CN110658344A (zh)
CA (1) CA2920066A1 (zh)
HK (1) HK1225443A1 (zh)
WO (1) WO2015028469A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
CN106018789A (zh) * 2016-08-03 2016-10-12 北京德奥平生物技术有限公司 一种st2定量检测方法及试剂盒
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US11942219B1 (en) * 2017-09-25 2024-03-26 Cerner Innovation, Inc. Determining a cardiovascular ischemic event and decision support tool
CN110361544A (zh) * 2019-07-29 2019-10-22 清华大学深圳研究生院 P1np检测试纸、p1np检测试剂盒和检测方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5695761A (en) 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
WO2000070051A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
JP4741249B2 (ja) * 2002-11-16 2011-08-03 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP1929295A4 (en) * 2005-08-30 2010-03-17 Biosite Inc USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
US20090240439A1 (en) * 2005-08-31 2009-09-24 Inverness Medical Switzerland Gmbh Predicting responses to drugs or drug cadidates
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
BRPI0715126B8 (pt) 2006-08-04 2021-07-27 Medizinische Hochschule Hannover métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
EP1884777A1 (en) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
EP2115477B1 (en) * 2007-01-25 2015-06-24 Roche Diagnostics GmbH Use of igfbp-7 in the assessment of heart failure
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
EP2201383B1 (en) * 2007-10-10 2014-01-15 Roche Diagnostics GmbH Means and methods for monitoring myocardial infarction and its treatment
WO2009058729A2 (en) * 2007-10-29 2009-05-07 Schering Corporation Thiazole carboxamide derivatives and their to treat cancer
WO2009079773A1 (en) * 2007-12-21 2009-07-02 Mcmaster University Method for assessing risk of heart failure
EP2237785B1 (en) * 2007-12-31 2015-12-23 Emory University Triarylmethane analogs and their use in treating cancers
US8632764B2 (en) * 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
EP2294423A1 (en) 2008-05-15 2011-03-16 F. Hoffmann-La Roche AG Multimarker panel for the differentiation of dilated cardiomyopathy and as basis for a differential therapy and its result
WO2009144307A1 (en) * 2008-05-29 2009-12-03 F. Hoffmann-La Roche Ag MEANS AND METHODS FOR IDENTIFYING A SUBJECT BEING SUSCEPTIBLE TO A CARDIAC THERAPY BASED ON DETERMINATION OF A CARDIAC TROPONIN, sCD40L AND C-REACTIVE PROTEIN
NZ607703A (en) * 2008-10-21 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2545757C2 (ru) * 2008-10-30 2015-04-10 Сантр Де Решерш Пюблик Де Ля Сантэ Биомаркеры
WO2010057135A2 (en) * 2008-11-14 2010-05-20 The Regents Of The University Of California Methods and compositions for predicting a subject's susceptibility to and risk of developing type 2 diabetes
CA2756120C (en) * 2009-04-27 2022-08-30 F. Hoffmann-La Roche Ag Use of endostatin as a marker of heart failure
JP5715641B2 (ja) * 2009-11-27 2015-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 急性胸痛を伴い、心筋梗塞を伴わない患者において、心虚血を診断およびモニターするための方法
AU2011238708B2 (en) * 2010-03-29 2016-02-11 The Trustees Of The University Of Pennsylvania Pharmacologically Induced Transgene Ablation system
JP2013536408A (ja) * 2010-07-02 2013-09-19 ビージー メディシン， インコーポレイテッド ガレクチン−３測定によりモニタリングされるスタチン療法
EP2367006A1 (en) * 2010-08-24 2011-09-21 Roche Diagnostics GmbH PLGF-based means and methods for diagnosing cardiac causes in acute inflammation
WO2012028713A1 (en) * 2010-09-02 2012-03-08 Roche Diagnostics Gmbh Method for diagnosing and monitoring the cardiac pathophysiological state in a subject undergoing or having undergone percutaneous coronary intervention (pci)
US20120219943A1 (en) * 2011-02-03 2012-08-30 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure

Also Published As

Publication number Publication date
JP2016529505A (ja) 2016-09-23
CN105659095A (zh) 2016-06-08
CN105659095B (zh) 2019-11-05
WO2015028469A2 (en) 2015-03-05
EP2843414B1 (en) 2018-09-19
US20160169911A1 (en) 2016-06-16
US11460474B2 (en) 2022-10-04
EP3441768A2 (en) 2019-02-13
US10234464B2 (en) 2019-03-19
US20220206015A1 (en) 2022-06-30
WO2015028469A3 (en) 2015-05-07
CN110658344A (zh) 2020-01-07
CA2920066A1 (en) 2015-03-05
JP6625535B2 (ja) 2019-12-25
EP3441768A3 (en) 2019-03-20
JP6934508B2 (ja) 2021-09-15
JP2021185371A (ja) 2021-12-09
EP2843414A1 (en) 2015-03-04
JP2020046432A (ja) 2020-03-26
US20190154706A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
HK1215374A1 (zh) 依魯替尼聯合療法
GB201321743D0 (en) Therapeutic agents
EP2867896A4 (en) RHYTHM OF CONTENT
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
HK1225443A1 (zh) 在心力衰竭中用於抑制素治療分層的標記物
GB201321745D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic
GB201321731D0 (en) Therapeutic agents
GB201321748D0 (en) Therapeutic agents
ZA201507755B (en) Tumor-selective combination therapy
GB201321749D0 (en) Therapeutic agents